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Abstract 
Word count: 204 
 
Background. It has recently been shown that systemic endothelial dysfunction is associated 
with airflow limitation in COPD. We conducted this ex vivo study to assess whether 
endothelial dysfunction of pulmonary arteries of former smokers was associated with 
modifications of airway functions.  
Methods. Pharmacological experiments were conducted on arterial and bronchial rings 
obtained from lung specimen of 20 patients: 13 smokers without COPD and 7 smokers with 
mild to moderate COPD (GOLD class I or II). The impairment of acetylcholine-mediated 
vasodilation (constriction) of preconstricted arterial rings defined endothelial dysfunction. 
Resting tone (initial and after a contraction test) and cGMP-mediated dilation of bronchial 
rings in response to zaprinast were evaluated. 
Results. Initial airway resting tone was correlated with airflow limitation (FEV1 % predicted: 
Rho= -0.49; p=0.032). The acetylcholine response of arterial rings was correlated with 
zaprinast-induced bronchodilation (Rho=0.54, p=0.019). Patients with endothelial dysfunction 
(n=5), as compared with those displaying no dysfunction (n=15), were characterized by an 
increased resting tone (after contraction test), an impaired response to zaprinast but a similar 
degree of airflow limitation (FEV1). 
Conclusion. Endothelial dysfunction of pulmonary arteries is associated with increased 
resting tone and impaired cGMP-mediated dilation of airways in former smokers, suggesting 
common underlying mechanisms of pulmonary arterial and bronchial dysfunctions. 
 
 
Key words: zaprinast, acetylcholine, bronchial ring, arterial ring, endothelial dysfunction 
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1. Introduction 
 
Recent researches on the pathogenesis of chronic obstructive pulmonary disease (COPD) 
suggest that perturbations in the vasculature may occur early in COPD [1-3]. Nitric oxide 
(NO)-mediated, endothelium-dependent relaxation provoked by adenosine diphosphate and 
acetylcholine is attenuated in the excised pulmonary arteries of patients with COPD compared 
with those of smoking and non-smoking control subjects [4]. Barr and colleagues 
demonstrated that impaired flow-mediated dilation, assessed by brachial artery flow-mediated 
dilation, is associated with low pulmonary function and emphysema in ex-smokers [1]. In this 
latter study, a linear relationship was demonstrated between flow-mediated dilation and post-
bronchodilator FEV1, and the magnitude of this association was the same in former smokers 
who had not developed COPD (FEV1/FVC ≥ 70%) as in the overall sample (mild to severe 
COPD). The authors postulated that the systemic nature of endothelial function made likely 
the alteration of endothelial reactivity in the pulmonary circulation. Based on this assumption, 
one may hypothesize that endothelial dysfunction of pulmonary arteries would be associated 
with impaired airway function. Accordingly, Peinado and colleagues showed that maximal 
relaxation of pulmonary arterial rings induced by acetylcholine is correlated with the 
FEV1/FVC ratio of COPD patients [4]. Inasmuch as endothelial dysfunction is associated with 
dysregulated nitric oxide (NO) metabolism, we speculated that NO-mediated bronchodilation 
would also be impaired. We therefore conducted this study to assess whether endothelial 
dysfunction of pulmonary arteries was associated with modifications of the level of resting 
tone of isolated airways and their cGMP-mediated dilation. Both parameters are NO-
dependent, and the former has previously been suggested to be associated with the level of 
airflow limitation [5]. 
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2. Material and Methods 
 
2.1. Patients 
Consecutive patients referred for lung surgical procedure (lobectomy or pneumonectomy for 
lung tumour) were eligible. Since impaired flow-mediated systemic dilation has been 
associated with low pulmonary function in former smokers, only ex-smokers were included 
(>15 Pack-Year). Based on the post-bronchodilator value of pre-operative pulmonary function 
test, patients were classified according to GOLD criteria [6]. All patients were informed of 
these biological experiments (bioethics’ law of august 2004). This study was approved by our 
Institutional Review Board. 
 
2.2. Pharmacological studies  
Just after resection, segments of pulmonary arteries and bronchi were taken from an area as 
far as possible from the tumour and were dissected free of parenchyma. Arterial rings were 
evaluated immediately after dissection, whereas bronchial rings were placed in oxygenated 
Krebs’s solution and stored overnight at 4°C, as previously described [5, 7, 8]. 
Intralobar arterial rings (inside diameter of 1.5-2 mm) or bronchial rings (inside diameter 1-2 
mm) were suspended on tissue hooks in 5 ml organ baths containing Krebs-Henseleit solution 
(NaCl, 119 mM; KCl, 5.4 mM; CaCl2, 2.5 mM; KH2PO4, 1.2 mM; MgSO4, 1.2 mM; 
NaHCO3, 25 mM; glucose, 11.7 mM), gassed with 95% O2: 5% CO2 and maintained at 37°C 
(pH 7.4). Each preparation was connected to a force displacement transducer (Statham UF-1) 
and isometric tension changes recorded in a computer (acquisition system: EMKA France, 
Bourre, France). All conditions were run in duplicate (when the duplicate experiments show 
discordant values, no result is given). 
2.2.1. Arterial experiments: 
 Revised manuscript – Changes in red - 5 - 
Endothelium-dependent relaxation was assessed by measuring the responses to acetylcholine 
(ACh, Pharmacie Centrale des Hôpitaux, Paris, France) in vessels preconstricted with L-
phenylephrine dichloride (10-5 M). Relaxation to ACh was expressed as a percentage of 
relaxation of phenylephrine induced tone. The absence of ACh-induced dilation or even a 
contractile response defined endothelial dysfunction, which constitutes a stringent definition 
that is based on the upper normal limit of the response in non smokers with normal lung 
function in our laboratory.  accordingly to previous experiments done in an historical group of 
non smokers. We previously demonstrated that the decrease in vascular reactivity was not due 
to endothelial damage during manipulations [7]. 
2.2.2. Bronchial experiments: 
After the initial loading of 2.5 g and subsequent equilibrium period, an initial resting tension 
(RT1) was obtained, bronchial viability was assessed using 10-3 M ACh. Then a new resting 
tension (RT2) was obtained, and a dose response curve to zaprinast (10-8 to 10-5 M) was 
conducted. At the end of the experiment, after an equilibrium period to resting tension, 
maximal dilation (10-3 M theophylline) was assessed, as previously described [9]. The absence 
of epithelial damage has also been checked in preliminary experiments [5]. Results were 
expressed as raw values (g) or percentage of theophylline-induced relaxation, as specified. 
The investigators performing bronchial experiments were blinded for the results of vascular 
experiments. 
 
2.3. Statistical analyses 
Results are expressed as median [interquartile range]. Data were analyzed using Statview 5.0 
(SAS Institute, Inc, North Carolina). For intergroup comparisons, categorical variables were 
compared using the chi-squared test or Fisher’s exact test, and continuous variables were 
compared using the Mann-Whitney U test or Kruskal Wallis test as appropriate. For 
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intragroup comparisons, continuous variables were compared using the Wilcoxon paired test. 
The Spearman’s rank correlation coefficient was used to examine possible correlation 
between two variables. A P value less than 0.05 was considered as significant. 
 
3. Results 
 
The clinical and functional characteristics of the 20 patients who were included are described 
in table 1. The characteristics of patients with and without dysfunction were similar. The 
figure 1 shows acetylcholine response of preconstricted arterial rings in patients with (n=5) 
and without endothelial dysfunction (n=15).  
The degree of airflow limitation was significantly correlated with the level of initial resting 
tension (RT1) (Rho= -0.49; p=0.032), and tended to be correlated with theophylline-induced 
maximal dilation (Rho= -0.38, p=0.096). 
The response to acetylcholine (constriction to dilation) of arterial rings was correlated with 
the degree of zaprinast-induced bronchodilation (figure 2), and tended to be correlated with 
the FEV1/FVC ratio (with ACh 10-5 M, Rho=0.37, p=0.11). 
The figure 3 shows that patients with endothelial dysfunction (n=5), as compared to those 
without dysfunction (n=15), were characterized by a higher level of resting tone after 
acetylcholine-induced contraction (RT2) and higher levels of tension under each single 
concentration of zaprinast (figure 3, upper panel). Since the level of RT2 was significantly 
different between the two groups of patients, their response to zaprinast was further evaluated 
as percentage of theophylline-induced maximal dilation (similar for the two groups). The 
impaired response to zaprinast is further confirmed (figure 3, lower panel), suggesting an 
impairment of cGMP-mediated dilation in COPD patients with endothelial dysfunction. 
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4. Discussion 
 
4.1. Background 
It has been shown that an impairment of flow-mediated dilation in systemic circulation occurs 
early in COPD, and is associated with airflow limitation, independently of smoking history, 
further suggesting a link between vascular and bronchial functions [1]. We suggest that in 
former smokers, endothelial dysfunction of pulmonary arteries is associated with impairment 
of both spontaneous resting tone and cGMP-mediated dilation of airways, establishing a 
biological link between pulmonary arterial and bronchial functions. To our best knowledge, 
comparison of arterial and bronchial pharmacological functions obtained from the same lung 
sample has never been made, and the description of dysfunction of pulmonary arteries has 
been assessed in a very limited number of studies [4, 10, 11]. A recent pulmonary perspective 
supported by the National Heart, Lung, and Blood Institute stated that there is a need for 
methods linking in vitro observations to in vivo disease state with regard to airway smooth 
muscle function [12]. Along this line we show an inverse relationship between the level of 
resting tone and FEV1, which is consistent with the fact that increased smooth muscle tone 
may contribute to airflow limitation in COPD, as previously suggested [5, 13, 14]. In our 
limited series of patients, airflow limitation was similar whether or not endothelial 
dysfunction was present. Several factors have been shown to contribute to systemic 
endothelial dysfunction, and our study was not powered to describe clinical and functional 
factors associated with pulmonary endothelial dysfunction. 
 
4.1. Endothelial dysfunction 
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There is no consensual definition of pulmonary endothelial dysfunction, but we do think that 
the absence of acetylcholine-induced dilation or even contractile response constitutes a drastic 
definition. We observed that one quarter of our COPD patients displayed pulmonary 
endothelial dysfunction, which is in agreement with our subsequent results observed in a 
larger series [8]. No data are available in the literature for further comparison, but a ~30% 
incidence of pulmonary hypertension in COPD patients has been reported [10]. In the study of 
Peinado and colleagues in mild COPD patients (mean ± SD: 24.9 ± 22.9 %), the dilator 
response to acetylcholine was diminished as compared to non smokers (40.1 ± 22.0 %), 
without reaching statistical significance. The standard deviations of their results suggest that 
some COPD patients depicted a constrictor response to acetylcholine while almost all non 
smokers have a vasodilator response. Obviously, our results need to be confirmed in a larger 
sample of patients due to the restricted size of our sample with endothelial dysfunction. 
 
4.3. Bronchial dysfunction 
The nil to moderate degree of cGMP-mediated bronchial dilation that is evidenced is 
consistent with the results of other investigators [15-17], emphasising the confounding effect 
of underlying pathology (such as endothelial dysfunction) and the modest contribution of 
cGMP-mediated dilation in airways. The presence of a systemic endothelial dysfunction 
suggests an impairment of NO-mediated relaxation in COPD. Our results further argue for a 
generalized impairment of NO-dependent functions, affecting both vascular and bronchial 
lung compartments. Airway blood flow reactivity has also been shown to be impaired in ex-
smokers [18]. Mullershausen and colleagues have demonstrated a similar mechanism of 
desensitization of NO/cGMP signaling in smooth muscle of both aorta and bronchi of rats, 
involving phosphodiesterase (PDE) 5 activation [19], giving insight into the underlying 
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mechanisms of generalized endothelial dysfunction. An increased expression of PDE 5 in 
models of pulmonary hypertension has been demonstrated [20].  
Figure 3 shows that resting tension after ACh was higher in the group with endothelial 
dysfunction that could already be related to an impaired relaxation after contraction. The 
bronchial relaxation induced by the nonselective phosphodiesterase (PDE) inhibitor 
(theophylline) was similar whatever the presence or absence of impaired cGMP-dependent 
relaxation (see Figure 3). It first suggests that cAMP-dependent relaxation is preserved 
whatever the degree of impairment of cGMP-mediated relaxation. In human bronchial smooth 
muscle, the presence of PDE I, II, III, IV (cAMP specific) and V (cGMP specific) have been 
identified [16, 21, 22]. One should have expected that theophylline-induced relaxation would 
be lower in presence of an impairment of cGMP relaxation. Since theophylline, in addition to 
its PDE inhibitory activity, is an antagonist at adenosine receptors, blockade of adenosine 
activity has been proposed as a possible mechanism for theophylline's effects. Accordingly, 
Ethier and Madison have shown that, in addition to its well-established indirect effects on 
smooth muscle cells, adenosine also has direct effects on contractile signalling pathways since 
it mobilizes intracellular calcium stores [23]. This may explain why theophylline has a very 
potent bronchodilating effects ex vivo using a high concentration. 
 
4.4. Clinical perspectives 
Establishing a formal relationship between pulmonary vascular and bronchial functions is an 
important issue. We further suggest that NO-related dysfunction may participate in this link. 
Whether pulmonary endothelial dysfunction is associated with COPD morbidity warrants 
further studies. But we recently evidenced a frequent endothelial dysfunction of ex vivo 
pulmonary arteries of patients suffering from cystic fibrosis (that was associated with 
pulmonary hypertension), and we further demonstrated that criteria of mild pulmonary 
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vascular disease were evidenced in some patients with cystic fibrosis that participated in 
exercise limitation [24].  
Finally, it will deserve assessing the effects of statins on bronchial functions because 
reductions in COPD morbidity and mortality, and improvements in lung function, have been 
attributed to statin use. Insights into cellular mechanisms indicate that statins promote 
vasorelaxation partly by upregulating the expression of endothelial NO synthase [25]. 
 
4.5. Conclusion 
This is the first study suggesting that endothelial dysfunction of pulmonary arteries is 
associated with increased resting tone and impaired cGMP-mediated dilation of airways in 
former smokers, suggesting common underlying mechanisms of pulmonary arterial and 
bronchial dysfunctions. 
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Figure legends 
 
 
Figure 1: Acetylcholine-response of preconstricted arterial rings. 
 
Patients were divided according to their response to acetylcholine: endothelial dysfunction 
(grey circles) is defined by a constrictor response (negative values), while the normal 
response (white circle) is defined by dilation (positive values). Errors bars are 95% 
confidence interval. # denotes a P value < 0.05, * denotes a P value < 0.005. 
 
 
 
Figure 2: Relationship between acetylcholine-induced arterial and zaprinast-induced 
bronchial dilations. 
 
Acetylcholine-induced dilation of arterial rings is expressed as percentage of the constrictor 
response to phenylephrine (PE), whereas zaprinast-induced dilation of bronchial rings is 
expressed as percentage of maximal response to theophylline (theo). An equivalent molar 
concentration (10-5 M) for both drugs is selected for the figure, but the relationship between 
zaprimast (10-5 M) response and ACh was of borderline significance for ACh 10-7 M (p= 
0.057) and significant for ACh 10-6 M to 10-4 M (p= 0.022, figure and p= 0.024, respectively). 
Grey circles are patients with endothelial dysfunction (negative acetylcholine-induced dilation 
= constriction, n=5), whereas white circles are patients without endothelial dysfunction 
(n=15). 
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Figure 3: Zaprinast-induced bronchodilation. 
 
Patients are divided according the presence of endothelial dysfunction (grey bars, n=5) or its 
absence (white bars, n=15). Box and whisker plots show median, 25th and 75th percentile and 
10th and 90th percentile. 
 
Upper panel: Levels of tension (g) according to the condition, initial resting tone (RT1), 
constrictor response to acetylcholine (10-3 M Ach), resting tone after contraction (RT2), dose 
response to zaprinast (10-8 to 10-5 M), and maximal dilation induced by theophylline (10-3 M 
theo). # denotes a P value < 0.05, * denotes a P value < 0.01. 
Patients without endothelial dysfunction depicted a weak but highly significant dilator 
response to zaprinast as compared RT-2 level: 10-8 M zaprinast, p=0.009; 10-7 M, p=0.020; 
10-6 M, p=0.011; 10-5 M, p=0.002 (Wilcoxon paired test), whereas patients with dysfunction 
had no significant dilator response to zaprinast (p>0.05 for all concentrations, Wilcoxon test). 
 
Lower panel: Response to zaprinast expressed as percentage of maximal theo-induced dilation 
(10-8 to 10-5 M). A significant dilator response is evidenced in patients without endothelial 
dysfunction (trend for 10-7M, significant for 10-5 M). 
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Table 1. Characteristics of the patients. 
 
 
 
Characteristic Patients with ED 
n = 5 
Patients without ED 
n = 15 
P value 
 
Age, years  
Sex ratio, Female/Male 
Tobacco, Pack-years 
FEV1, % predicted 
Smokers without COPD, n 
GOLD class, n 
Class I 
Class II 
Preoperative chemotherapy, n 
 
61 [51-66] 
1/4 
30 [26-60] 
78 [72-99] 
3 
 
0 
2 
1 
 
64 [58-70] 
2/13 
50 [21-65] 
88 [75-99] 
10 
 
2 
3 
3 
 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
 
Results are expressed as median [interquartile range] 
ED denotes endothelial dysfunction; NS denotes non significant 
FEV1 denotes forced expiratory volume in one second (post-bronchodilator value) 
 
  
  
  
  
